Clinical trials: Intravenous Infusions
Resectable Colon Cancer, Resectable Non-small Cell Lung Cancer
Mechanism of Action Trial of ColoAd1
To assess the pattern of ColoAd1 viral delivery and viral expression within colon tumour tissue when administered by intra-tumoural injection or within colon, non-small cell lung, bladder and renal cell tumour tissues following…
- Conditions
- Resectable Colon Cancer, Resectable Non-small Cell Lung Cancer, Resectable Bladder Cancer, Resectable Renal Cell Carcinoma
- Trial name
- MOA (NCT02053220)
- Testing
- Colo-Ad1
- Where
- 2 sites in Spain
- Volunteers
- 17 people
- Sponsor
- Akamis Bio
Diabetes Mellitus, Type 2
Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.
- Trial name
- NCT01300260
- Testing
- LY2189265, Insulin, Glucose
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Chronic Obstructive Pulmonary Disease (COPD)
TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
The purpose of this study is to evaluate the absorption, distribution, metabolism and excretion of an investigational medication used to treat chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02772159
- Testing
- TD-4208
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Mylan Inc.
Healthy Volunteer
A Study of RO6926496 in Healthy Volunteers
This is a single center, randomized, investigator/subject blind, single ascending dose, placebo-controlled, parallel study that will evaluate the safety, tolerability and pharmacokinetics of RO6926496 in healthy male…
- Trial name
- NCT02281786
- Testing
- RO6926496
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Inflammation
Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers
The objective of the study is to investigate safety, tolerability, and pharmacokinetics of XG-102 following iv infusion of single escalating dose of 10, 40, and 80 µg/kg XG-102 to healthy male volunteers
- Trial name
- NCT01570205
- Testing
- XG-102
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Xigen SA
Major Depressive Disorder
Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression
The purpose of this study is to evaluate the efficacy and safety of vortioxetine given as a single intravenous dose of 25 mg at initiation of an oral vortioxetine regimen of 10 mg/day for 7 days
- Trial name
- NCT03766867
- Testing
- Vortioxetine infusion 25 mg, Vortioxetine tablets 10 mg/day
- Where
- 13 sites in Bulgaria, Estonia and 1 more
- Volunteers
- 80 people
- Sponsor
- H. Lundbeck A/S
Hypoplasminogenemia
A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial
The clinical trial is no longer enrolling and is currently closing and Prometic will continue to provide Plasminogen (Human) under a treatment protocol to subjects in the United States (US) with hypoplasminogenemia requiring…
- Trial name
- NCT03642691
- Testing
- Ryplazim
- Where
- 3 sites in United States
- Sponsor
- Prometic Biotherapeutics, Inc.
SMA
Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
Phase 3, open-label, single-arm, single-dose, trial of onasemnogene abeparvovec-xioi (gene replacement therapy) in patients with spinal muscular atrophy (SMA) Type 1 who meet enrollment criteria and are genetically defined by a…
- Trial name
- STRIVE-EU (NCT03461289)
- Testing
- Onasemnogene Abeparvovec-xioi
- Where
- 10 sites in Belgium, France and 2 more
- Volunteers
- 33 people
- Sponsor
- Novartis Gene Therapies
Rheumatoid Arthritis
Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis
This study will investigate the pharmacokinetic (PK) / total IL-1beta pharmacodynamic (PD) relationship in joint fluids of patients with rheumatoid arthritis (RA) treated with different doses of ACZ885 and to evaluate the impact…
- Trial name
- NCT00505089
- Testing
- ACZ885
- Where
- 9 sites in Belgium, Germany and 2 more
- Volunteers
- 11 people
- Sponsor
- Novartis
GI Adenocarcinoma
A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer
The purpose of this Phase 1 study is to determine if AMG 211 given as a continous intravenous (IV) infusion is safe and tolerable in adult participants that have advanced gastrointestinal adenocarcinoma.
- Trial name
- NCT02291614
- Testing
- AMG 211
- Where
- 5 sites in Germany, Netherlands
- Volunteers
- 45 people
- Sponsor
- Amgen
Primary Immune Deficiency Disorder
A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products
This is a safety study to evaluate the risk of low blood pressure in subjects with Primary Immune Deficiency disorder (PID) treated with Bivigam™ or another commercial product under real world conditions.
- Trial name
- NCT03037359
- Testing
- Bivigam, Other
- Where
- 17 sites in United States
- Volunteers
- 200 people
- Sponsor
- ADMA Biologics, Inc.
Advanced or Metastatic Solid Tumors, Cancer
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of SF1126 in patients with advanced or metastatic tumors by assessing the dose limiting toxicities (DLTs) and defining the maximum tolerated dose given twice…
- Conditions
- Advanced or Metastatic Solid Tumors, Cancer, Solid Cancers
- Trial name
- SF112600106 (NCT00907205)
- Testing
- SF1126
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Semafore Pharmaceuticals
Severe Sepsis, Septic Shock
A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock
The primary purpose of this study to evaluate the effect of two different doses of AZD9773 (CytoFab™) versus placebo on ventilator free days (VFDs) over the first 28 days after the start of dosing with AZD9773 in patients with…
- Trial name
- NCT01145560
- Testing
- AZD9773
- Where
- 52 sites in Australia, Belgium and 5 more
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Pulmonary Hypertension Due to Left Heart Disease
A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)
Researchers are looking for a better way to treat people who have pulmonary hypertension (PH) due to left heart disease. PH due to left heart disease is a condition of high blood pressure in the vessels of the lungs caused by…
- Trial name
- NCT06048120
- Testing
- BAY2701250 IV, BAY2701250 SC
- Where
- Germany
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Volunteers, Rheumatoid Arthritis
A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
The purpose of this study is to assess the safety and tolerability of CPTX2309 in healthy adult participants and adult participants with moderate to severe rheumatoid arthritis or systemic lupus erythematosus.
- Conditions
- Healthy Volunteers, Rheumatoid Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT06917742
- Testing
- CPTX2309
- Where
- 3 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Capstan Therapeutics
Rheumatoid Arthritis
Safety and Efficacy Study of Human Umbilical Cord-Derived Mesenchymal Stem Cells(BC-U001) for Rheumatoid Arthritis
BC-U001 is an allogeneic fresh human umbilical cord-derived mesenchymal stem cell product, which showed therapeutic potential for rheumatoid arthritis(RA) based on its anti-inflammatory, immunomodulatory and tissue repair…
- Trial name
- NCT04971980
- Testing
- hUC-MSC infusion (BC-U001)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Baylx Biotech Co., Ltd.
Healthy
Phase 1 Study of Trastuzumab Administered as a Single Intravenous Infusion
The primary objective of this study was to demonstrate pharmacokinetic similarity of Mylan trastuzumab (Hercules) versus EU-approved Herceptin® and US-licensed Herceptin® and pharmacokinetic similarity of EU-approved Herceptin®…
- Trial name
- NCT02594761
- Testing
- Hercules, Herceptin EU, Herceptin US
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Neoplasms
A Study of R547 in Patients With Advanced Solid Tumors.
This single arm study will determine the maximum tolerated dose, and recommended dose for further development, of R547, in patients with advanced solid tumors.
- Trial name
- NCT00400296
- Testing
- RG547
- Where
- 4 sites in United States
- Volunteers
- 58 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Conditions
- Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer
- Trial name
- NCT05005403
- Testing
- Azirkitug, Budigalimab, Bevacizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 694 people
- Sponsor
- AbbVie
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.